Editor's Note

Yesterday's casualties can come back from the dead. Stocks do stumble. However, what does not kill them makes them stronger.



NEW BULLISH Plays

XON - Intrexon Corp - Company Profile

Intrexon Corporation engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland. Company description from FinViz.com.

Intrexon just announced a deal with Surterra Wellness to produce cannabinoids using the Intrexon yeast fermentation technology. This is the second deal between the two companies. In March, Surterra licensed Intrexon's Botticelli plant propagation technology to improve cannabis crop yield and quality.

In the current deal Intrexon will receive $100 million over time including $15 million in Surterra shares. The cash will help on the cash burn problem. Intrexon had $181 million in cash at the end of March. Intrexon has dozens of products and technologies in the process of being commercialized.

In May and early June, the CEO bought 6 million shares in the open market in about 35 transactions. That is a roughly $30 million investment in Intrexon and as CEO he should know what is coming for the company.

Earnings August 8th.

Buy XON shares, currently $7.74, stop loss $6.75.
Optional: Buy Aug $8 call, currently .80, stop loss $6.75.



SNCR - Synchronoss Technologies - Company Profile

Synchronoss Technologies, Inc. provides cloud, digital, messaging, and Internet of Things (IoT) platforms, products, and solutions in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company's platforms, products, and solutions include digital experience management platform as a service, which includes digital journey creation and journey design products that use analytics that power digital advisor products for IT and business channel owners; and cloud sync, backup, storage, device set up, content transfer, and content engagement for user generated content. Its platforms, products, and solutions also comprise multi-channel messaging peer-to-peer communications and application-to-person commerce solutions; and IoT management technology for smart cities, smart buildings, automotive, and others. In addition, the company offers software development and customization services. Its products and platforms enable multiple converged communications, commerce and applications, and devices to deploy across a range of distribution channels, such as e-commerce, m-commerce, telesales, retail stores, and care and call centers, as well as self-service, indirect, and other outlets. The company markets and sells its services through direct sales force and strategic partners. Synchronoss Technologies, Inc. was founded in 2000 and is headquartered in Bridgewater, New Jersey. Company description from FinViz.com.

On June 6th, SNCR held an investor day and gave better than expected earnings guidance, plans to invest $20-$25 million on capturing future growth opportunities and reiterated its revenue guidance of $340-$355 million and adjusted EBITDA of $30-$40 million after those investments. This was a shock to the analysts in attendance. Shares rallied about 15%.

On June 18th, Roth Capital analyst Richard Baldry initiated coverage with a buy rating and $13 price target. SNCR was trading at $6.67 at the time. That price target was a 95% premium to the prior close. The analyst said SNCR had a "unique set" of cloud based products that cater to "important new strategic growth avenues for a broadening set of potential customers." Shares rallied $2 from the $6.66 close.

Since that analyst coverage, shares have been moving higher and closed at a 14-month high on Friday. Their all time high was near $50 and nobody expects them to reach that level in the near future but it does prove they can evolve after a year in the dumps.

If they break over the $8.50 level we could see a run to resistance at $12 in the near future.

Earnings August 8th.

Buy SNCR shares, currently $8.42, stop loss $7.45.
Optional: Buy September $10 call, currently 40 cents, no stop loss.



NEW BEARISH Plays

No New Bearish Plays